Schreiner MediPharm Light-Protect Label Being Used in Novel Cancer Drug Clinical Trial

Schreiner MediPharm, a Munich-based healthcare labeling company, announced that a customer, has chosen its specialty Light-Protect-Label for clinical trial of a novel antibody drug conjugate (ADC). The label provides light protection that “blinds the drug” to protect the light-sensitive active ingredient while enabling inspection of the vial contents in the original color, thereby neutralizing the investigational drug.

The customer is WuXi XDC, a leading contract research, development, and manufacturing organization (CRDMO) based China with a focus on antibody drug conjugates (ADCs) and other novel bioconjugates.

Schreiner MediPharm developed the opaque label, which has integrated UV and light protection and is suited to transparent vials; it completely wraps around the container and offers optimal light protection. At the same time, it supports a dependable and safe conduct of the clinical trial by reliably blinding the investigational drugs, the company says. A resealable inspection window enables an unadulterated view of the vial content; this is crucial for inspecting the condition and color of the reconstituted lyophilizate before it is administered, thus ensuring the efficacy of the medication.

The light protection solution, the company adds, is well-suited for use in antibody drug conjugates like the one in this trial. ADCs are an important innovation in cancer therapy because: “Through targeted delivery of drugs into specific tumor cells, they enable gentler and more effective treatment compared to conventional chemotherapies.” The technology acts directly on the cancer cell, largely sparing healthy cells and minimizing side effects.

Related:FDA Issues Final EO Site Change Guidance